Publications & Posters


FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model..
Deuschle U, Schüler J, Schulz A, Schlüter T, Kinzel O, Abel U, Kremoser C.
PLoS One. 2012;7(10):e43044
Synthetic farnesoid x receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice..
Hambruch E, Miyazaki-Anzai S, Hahn U, Matysik S, Boettcher A, Perovic-Ottstadt S, Schlüter T, Kinzel O, Krol HD, Deuschle U, Burnet M, Levi M, Schmitz G, Miyazaki M, Kremoser C.
J Pharmacol Exp Ther. 2012 Dec;343(3):556-67
Synthesis and pharmacological validation of a novel series of non-steroidal
FXR agonists
Abel U, Schlüter T, Schulz A, Hambruch E, Steeneck C, Hornberger M, Hoffmann T,
Perović-Ottstadt S, Kinzel O, Burnet M, Deuschle U, Kremoser C.

Bioorg Med Chem Lett. 2010 Aug 15;20(16):4911-7
Panning for SNuRMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulators.
Kremoser C, Albers M, Burrris TP, Deusche U, Koegl M.
Drug Discov Today. 2007 Oct;12(19-20):860-9. Epub 2007 Sep 19.
A Novel Principle for Partial Agonism of Liver X Receptor Ligands: COMPETITIVE RECRUITMENT OF ACTIVATORS AND REPRESSORS.
Albers M, Blume B, Schlueter T, Wright MB,
Kober I, Kremoser C, Deuschle U, Koegl M.

J Biol Chem. 2006 Feb 24;281(8):4920-30. Epub 2005 Dec 13.
Automated yeast two-hybrid screening for nuclear receptor-interacting proteins.
Albers M, Kranz H, Kober I, Kaiser C, Klink M, Suckow J, Kern R, Koegl M.
Mol Cell Proteomics. 2005 Feb;4(2):205-13. Epub 2004 Dec 15.


FXR agonist Px-102 improves hepatic steatosis in NAFLD mouse models. PDF
The Asian Pacific Association for the Study of the Liver: "APASL Liver week", Juni 6-10, 2013 Singapore, Malysia
Synthetic Farnesoid X Receptor agonist PX20606 demonstrates anti-atherosclerotic effects and lowers cholesterol in HDL2 but not in HDL3 subfractions.PDF
DKFZ-ZMBH Alliance Forum: "Metabolism 2012 From Signaling to Disease", November 15-16, 2012 Heidelberg, Germany
Strong anti-steatotic and anti-fibrotic effects of novel FXR agonists in a murine NASH model that resembles human NASH.PDF
The 9th JSH Single Topic Conference :"NASH 2010" November 18-19, 2010 Tokyo, Japan